UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis

The New England journal of medicine, 2019-06, Vol.380 (25), p.2406-2417

2019

Volltextzugriff (PDF)

Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study

Multiple sclerosis, 2018-10, Vol.24 (12), p.1594-1604

2018

Volltextzugriff (PDF)

Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers

Therapeutic advances in neurological disorders, 2019-06, Vol.12, p.1756286419854986-1756286419854986

2019

Volltextzugriff (PDF)

Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies

Multiple sclerosis, 2022-01, Vol.28 (1), p.111-120

2022

Volltextzugriff (PDF)

Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets

Multiple sclerosis, 2018-02, Vol.24 (2), p.222-226

2018

Volltextzugriff (PDF)

Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study

Multiple sclerosis, 2019-05, Vol.25 (6), p.819-827

2019

Volltextzugriff (PDF)

Determination of a clinically effective evobrutinib dose: Exposure–response analyses of a phase II relapsing multiple sclerosis study

Clinical and translational science, 2022-12, Vol.15 (12), p.2888-2898

2022

Volltextzugriff (PDF)

Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing–remitting multiple sclerosis: the CLARITY Extension study

Therapeutic advances in neurological disorders, 2018-01, Vol.11, p.1756285617753365-1756285617753365

2018

Volltextzugriff (PDF)

Facing the urgency of therapies for progressive MS - a Progressive MS Alliance proposal

Nature reviews. Neurology, 2021-03, Vol.17 (3), p.185-192

2021

Volltextzugriff (PDF)

Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS

Journal of neurology, 2020, Vol.267 (1), p.64-75

2020

Volltextzugriff (PDF)

Sodium phenylbutyrate prolongs survival and regulates expression of anti‐apoptotic genes in transgenic amyotrophic lateral sclerosis mice

Journal of neurochemistry, 2005-06, Vol.93 (5), p.1087-1098

2005

Volltextzugriff (PDF)

Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1

BMC neurology, 2018-09, Vol.18 (1), p.143-143, Article 143

2018

Volltextzugriff (PDF)

Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives

Neurology and therapy, 2024-04, Vol.13 (2), p.283-322

2024

Volltextzugriff (PDF)

Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis

Multiple sclerosis journal - experimental, translational and clinical, 2021-07, Vol.7 (3), p.20552173211024298-20552173211024298

2021

Volltextzugriff (PDF)

Rationale for the Use of Histone Deacetylase Inhibitors as a Dual Therapeutic Modality in Multiple Sclerosis

Epigenetics, 2006-04, Vol.1 (2), p.67-75

2006

Volltextzugriff (PDF)

Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study

BMC neurology, 2018-05, Vol.18 (1), p.68-68, Article 68

2018

Volltextzugriff (PDF)

Functional Characterization of JMJD2A, a Histone Deacetylase- and Retinoblastoma-binding Protein

The Journal of biological chemistry, 2005-08, Vol.280 (31), p.28507-28518

2005

Volltextzugriff (PDF)

Effect of treatment with interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: a 24-week, controlled pilot study

PloS one, 2014-03, Vol.9 (3), p.e91098-e91098

2014

Volltextzugriff (PDF)

The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study

Multiple sclerosis journal - experimental, translational and clinical, 2017-10, Vol.3 (4), p.2055217317732802-2055217317732802

2017

Volltextzugriff (PDF)

Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study

Multiple sclerosis journal - experimental, translational and clinical, 2021, Vol.7 (1), p.2055217321990852-2055217321990852

2021

Volltextzugriff (PDF)

A compendium of gene expression in normal human tissues

Physiological genomics, 2001-12, Vol.7 (2), p.97-104

2001

Volltextzugriff (PDF)

Noninfectious entry of HIV-1 into peripheral and brain macrophages mediated by the mannose receptor

Proceedings of the National Academy of Sciences - PNAS, 2007-03, Vol.104 (12), p.5097-5102

2007

Volltextzugriff (PDF)

Molecular signature of late-stage human ALS revealed by expression profiling of postmortem spinal cord gray matter

Physiological genomics, 2004-01, Vol.16 (2), p.229-239

2004

Volltextzugriff (PDF)

Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study

BMC neurology, 2012-12, Vol.12 (1), p.154-154, Article 154

2012

Volltextzugriff (PDF)

The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review

Drugs (New York, N.Y.), 2020-12, Vol.80 (18), p.1901-1928

2020

Volltextzugriff (PDF)

1 – 25 von 151

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(143)
Mit Volltextzugriff
(81)

Publikationsform

Artikel
(150)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(60)
Life Sciences & Biomedicine
(57)
Multiple Sclerosis
(49)
Humans
(48)
Neurosciences & Neurology
(33)
Clinical Neurology
(25)
Female
(25)
Male
(25)
Adult
(24)
Middle Aged
(20)
Multiple Sclerosis, Relapsing-Remitting - Drug Therapy
(20)
Neurology
(16)
Neurosciences
(16)
Cladribine Tablets
(15)
Magnetic Resonance Imaging
(15)
Patients
(15)
Multiple Sclerosis - Drug Therapy
(13)
Cladribine
(10)
Clarity
(10)
Treatment Outcome
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis

Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study

Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers

Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies

Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets

Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study

Determination of a clinically effective evobrutinib dose: Exposure–response analyses of a phase II relapsing multiple sclerosis study

Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing–remitting multiple sclerosis: the CLARITY Extension study

Facing the urgency of therapies for progressive MS - a Progressive MS Alliance proposal

Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS

Sodium phenylbutyrate prolongs survival and regulates expression of anti‐apoptotic genes in transgenic amyotrophic lateral sclerosis mice

Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1

Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives

Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis

Rationale for the Use of Histone Deacetylase Inhibitors as a Dual Therapeutic Modality in Multiple Sclerosis

Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study

Functional Characterization of JMJD2A, a Histone Deacetylase- and Retinoblastoma-binding Protein

Effect of treatment with interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: a 24-week, controlled pilot study

The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study

Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study

A compendium of gene expression in normal human tissues

Noninfectious entry of HIV-1 into peripheral and brain macrophages mediated by the mannose receptor

Molecular signature of late-stage human ALS revealed by expression profiling of postmortem spinal cord gray matter

Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study

The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review

Suchergebnisse filtern